- $1.77bn
- $1.24bn
- $68.56m
Brief: Vir Biotechnology Q2 Cash & Investments USD 1,430 Million
Vir Biotechnology Inc expected to post a loss of 90 cents a share - Earnings Preview
Brief: Vir Biotechnology Receives FDA IND Clearance And Fast Track Designation For Tobevibart And Elebsiran For The Treatment Of Chronic Hepatitis Delta Infection
U.S. RESEARCH ROUNDUP-Chord Energy, PVH, Saia
Brief: Vir Biotechnology Says Tobevibart Monotherapy, Combination Therapy With Elebsiran Achieved High Virologic Response
Vir Biotechnology Inc reports results for the quarter ended in March - Earnings Summary
Brief: Vir Biotechnology Q1 Cash & Investments USD 1,510 Million
Vir Biotechnology Inc expected to post a loss of $1.05 a share - Earnings Preview
Brief: Vir Biotechnology Completes Enrollment Of Phase 2 Chronic Hepatitis Delta Solstice Trial
U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Intuit, Penumbra
Vir Biotechnology Inc reports results for the quarter ended in December - Earnings Summary
Brief: Vir Biotechnology Inc On Feb 21, Co And Glaxo Wellcome Uk Limited Entered Into A Letter Agreement
Brief: Vir Biotechnology Reducing Workforce By Approximately 12%
Vir Biotechnology to cut about 75 jobs, shut some facilities (updated)
Vir Biotechnology to cut about 75 jobs, shut some facilities
Vir Biotechnology Inc reports results for the quarter ended in September - Earnings Summary
Brief: Vir Biotechnology Q3 Revenue USD 2.6 Million
Vir Biotechnology Inc expected to post a loss of $1.21 a share - Earnings Preview
Brief: Vir Biotechnology Appoints Executive Vice President And Chief Scientific Officer